{"id":"NCT02682264","sponsor":"Cassiopea SpA","briefTitle":"An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris","officialTitle":"An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice-Daily in Subjects With Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-09","primaryCompletion":"2018-08-31","completion":"2018-08-31","firstPosted":"2016-02-15","resultsPosted":"2020-11-17","lastUpdate":"2020-11-17"},"enrollment":609,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"CB-03-01 cream, 1%","otherNames":["cortexolone 17α-propionate","clascoterone (USAN, INN)"]}],"arms":[{"label":"CB-03-01 cream, 1%","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to determine the long-term safety of CB-03-01 cream, 1% applied twice daily for an additional nine months in study participants with acne vulgaris that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months.","primaryOutcome":{"measure":"Number of Participants With Any Local and Systemic Treatment Emergent Adverse Events","timeFrame":"up to 52 weeks","effectByArm":[{"arm":"CB-03-01 Cream, 1%","deltaMin":58,"sd":null},{"arm":"CB-03-01 Cream, 1% (Vehicle Arm)","deltaMin":52,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":74,"countries":["United States","Bulgaria","Georgia","Poland","Romania","Serbia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":317},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Respiratory tract infection viral","Sinusitis","Application site acne"]}}